The FDA has informed Eli Lilly that it plans to convene a panel of independent experts to learn more about the safety and efficacy of donanemab, the company’s proposed Alzheimer’s drug. The move delays an FDA decision on the drug until at least later this year.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
